COVID-19 mRNA vaccines were developed with insufficient testing, skipping safety trials.
mRNA vaccine research began in the 1990s when scientists discovered that synthetic mRNA could trigger immune responses. Katalin Karikó and Drew Weissman's breakthrough work (for which they won the 2023 Nobel Prize) on pseudouridine modifications came in 2005, solving the problem of inflammatory mRNA reactions. By 2020, when COVID-19 emerged, the platform was already decades old with prior human trials for influenza, cancer, and RSV vaccines. The clinical trials for COVID mRNA vaccines didn't skip phases; they ran phases 1, 2, and 3 simultaneously rather than sequentially, a compression of timeline enabled by massive funding and enrollment, not a reduction of safety rigor. The Phase 3 trials included 44,000-45,000 participants and followed participants for the same duration as any vaccine trial, collecting the same safety data. What actually accelerated was bureaucratic process (priority FDA review) and manufacturing (using existing capacity), not scientific validation. The 'rushed' narrative ignores that millions died of COVID while vaccines sat in development, speed was ethical. Post-deployment monitoring has now tracked over 13 billion vaccine doses globally, revealing safety profiles consistent with Phase 3 trials.